Log In
Print this Print this

Pandemic Influenza Vaccine Enhancement Patch (IC82)

  Manage Alerts
Collapse Summary General Information
Company Valneva SE
DescriptionIntercell's adjuvant Vaccine Enhancement Patch (VEP) containing LT, a heat-labile enterotoxin from Escherichia coli, in combination with GlaxoSmithKline's H5N1 pandemic antigen
Molecular Target Influenza antigen
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase I/II
Standard IndicationInfluenza virus
Indication DetailsVaccinate against pandemic influenza virus
Regulatory Designation
PartnerGlaxoSmithKline plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today